The combination of Ketorolac (0.5% w/v) and Moxifloxacin (0.5% w/v) in an ophthalmic formulation represents a synergistic approach to managing eye conditions where both infection control and inflammation relief are essential. Moxifloxacin, a fourth‑generation fluoroquinolone antibiotic, provides broad‑spectrum antibacterial coverage, effectively targeting common ocular pathogens responsible for infections such as conjunctivitis and keratitis. Its mechanism of action involves inhibiting bacterial DNA replication, ensuring rapid suppression of microbial growth. Ketorolac, on the other hand, is a non‑steroidal anti‑inflammatory drug (NSAID) that works by reducing prostaglandin synthesis, thereby alleviating pain, redness, and swelling associated with ocular inflammation. Together, these agents deliver a dual benefit: Moxifloxacin addresses the underlying infection, while Ketorolac mitigates the inflammatory response, enhancing patient comfort and promoting faster recovery. This combination is particularly useful in post‑operative ophthalmic care, such as after cataract surgery, where the risk of infection and inflammation coexist. By integrating antimicrobial and anti‑inflammatory properties in a single preparation, the formulation simplifies treatment regimens, improves compliance, and supports optimal healing outcomes. Overall, Ketorolac with Moxifloxacin eye drops serve as a comprehensive solution for maintaining ocular health, ensuring both protection against bacterial invasion and relief from inflammatory discomfort.